The Trump administration has pledged $812 million (AED 2.98 billion) to boost the US manufacturing of medicines needed to treat the coronavirus.
It's aimed to end dependence on other countries, and boost their own supply chain.
The four-year contract, worth $354 million, which has been awarded to Virginia-based Phlow Corp can be extended to a total of $812 million over 10 years.
It will develop essential drugs and not vaccines, officials explained.
"For far too long, we've relied on foreign manufacturing and supply chains for our most important medicines and active pharmaceutical ingredients while placing America's health, safety, and national security at grave risk," Peter Navarro, director of the White House Office of Trade and Manufacturing Policy, said in a statement.
China launches mission to return samples from Moon's far side
Fresh chaos, arrests on US college campuses as police flatten camp at UCLA
Indonesia to permanently relocate 10,000 people after Ruang volcano eruptions
Strong quake strikes Philippines, aftershocks expected
India's Rahul Gandhi to contest elections from family borough
Bus falls into ravine in Pakistan's far north, killing 20
Death toll from rains in southern Brazil climbs to 29
Mexican authorities search for missing Australian, US tourists
